The Current Ratio as of November 2024 (TTM) for SAB Biotherapeutics, Inc. (SABS) is 3.69

According to SAB Biotherapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 3.69. This represents a change of -26.31% compared to the average of 5.01 of the last 4 quarters.

SAB Biotherapeutics, Inc. (SABS) Historical Current Ratio (quarterly & annually)

How has SABS Current Ratio performed in the past?

The mean historical Current Ratio of SAB Biotherapeutics, Inc. over the last ten years is 2.80. The current 3.69 Current Ratio has changed 13.07% with respect to the historical average. Over the past ten years (40 quarters), SABS's Current Ratio was at its highest in in the March 2021 quarter at 14.01. The Current Ratio was at its lowest in in the September 2023 quarter at 0.34.

SAB Biotherapeutics, Inc. (SABS) Current Ratio by Quarter and Year

Discovering the peaks and valleys of SAB Biotherapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

SAB Biotherapeutics, Inc. (SABS) Average Current Ratio

How has SABS Current Ratio performed in the past?

The current Current Ratio of SAB Biotherapeutics, Inc. (SABS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

SAB Biotherapeutics, Inc. (SABS) Current Ratio vs. Peers

How is SABS’s Current Ratio compared to its peers?

SAB Biotherapeutics, Inc.’s Current Ratio is less than Comera Life Sciences Holdings, Inc. (0), greater than Processa Pharmaceuticals, Inc. (0.90), less than Fresh Tracks Therapeutics, Inc. (3.97), less than Third Harmonic Bio, Inc. (6.98), less than Cingulate Inc. (42.50), less than Anebulo Pharmaceuticals, Inc. (7.35), greater than Cadrenal Therapeutics, Inc. Common Stock (3.45), greater than Monopar Therapeutics Inc. (3.69), less than Unicycive Therapeutics, Inc. (5.41K), greater than Quoin Pharmaceuticals, Ltd. (3.61), greater than Cardio Diagnostics Holdings, Inc. (3.02), less than Virax Biolabs Group Limited (8.51), less than PaxMedica, Inc. Common Stock (25.94), greater than null (0.38),

Build a custom stock screener for SAB Biotherapeutics, Inc. (SABS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like SAB Biotherapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

SAB Biotherapeutics, Inc. (SABS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like SAB Biotherapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.